"For me, the take-home message is that reduced or even no-narcotic discharge for patients after kidney surgery is feasible, and that it really should be our mindset of, can we reduce the amount of opioids we use?" says Craig G. Rogers, MD.
In this video, Craig G. Rogers, MD, and Katherine Wang, MD, discuss the Urology Practice study “Practice-Level Variation in Opioid-Free Discharge Following Surgery for T1 Renal Masses: A MUSIC-KIDNEY Analysis.” Rogers is director of renal surgery at Henry Ford Hospital, director of urologic oncology at Henry Ford West Bloomfield Hospital, program director of the urology clinical research fellowship, program director of the robotic urology fellowship, medical director of the Vattikuti Urology Institute Center for Outcomes Research Analytics and Evaluation, and chair of the Henry Ford Department of Urology at Henry Ford Health System in Detroit, Michigan. Wang is a research fellow in the department of urology at Henry Ford Health System in Detroit, Michigan.
Rogers: For me, the take-home message is that reduced or even no-narcotic discharge for patients after kidney surgery is feasible, and that it really should be our mindset of, can we reduce the amount of opioids we use? And that will take intentionality on the part of the surgeon as part of the team, whether it's the APPs that are part of the discharge, the residents; everyone needs to be on board with this. We get in these ruts of just doing things the same all the time, because that's the way we've always done it. And it takes research like this to kind of wake up a little bit to say, we don't always have to do it the same way. There are better ways, safer ways of doing things. So my take-home message is sort of a call to action that we can look at how we're doing our pain control in our patients.
Is there anything you would like to add?
Wang: I would just like to plug that MUSIC did make a brochure for patient education on managing pain. And that's been something that we've been utilizing as well as other practices participating in MUSIC. We've never actually evaluated what patients think of it, but I'm sure it's been helpful for them to understand what are the implications of your procedure and what are the ways that we can manage your pain aside from opioids.
This transcription was edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.